282 related articles for article (PubMed ID: 25481944)
1. [Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Samsonova MG; Samsonov AM; Kolchanov NA; Ivanisenko VA
Biofizika; 2013; 58(5):758-74. PubMed ID: 25481944
[TBL] [Abstract][Full Text] [Related]
2. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA
PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004
[TBL] [Abstract][Full Text] [Related]
3. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
[TBL] [Abstract][Full Text] [Related]
4. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
5. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
He Y; King MS; Kempf DJ; Lu L; Lim HB; Krishnan P; Kati W; Middleton T; Molla A
Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
[TBL] [Abstract][Full Text] [Related]
6. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
[TBL] [Abstract][Full Text] [Related]
7. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A
Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230
[TBL] [Abstract][Full Text] [Related]
8. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Dahl G; Sandström A; Akerblom E; Danielson UH
Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
[TBL] [Abstract][Full Text] [Related]
9. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
Lin C; Gates CA; Rao BG; Brennan DL; Fulghum JR; Luong YP; Frantz JD; Lin K; Ma S; Wei YY; Perni RB; Kwong AD
J Biol Chem; 2005 Nov; 280(44):36784-91. PubMed ID: 16087668
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.
Horscroft N; Bellows D; Ansari I; Lai VC; Dempsey S; Liang D; Donis R; Zhong W; Hong Z
J Virol; 2005 Mar; 79(5):2788-96. PubMed ID: 15708997
[TBL] [Abstract][Full Text] [Related]
11. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
13. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
Tong X; Arasappan A; Bennett F; Chase R; Feld B; Guo Z; Hart A; Madison V; Malcolm B; Pichardo J; Prongay A; Ralston R; Skelton A; Xia E; Zhang R; Njoroge FG
Antimicrob Agents Chemother; 2010 Jun; 54(6):2365-70. PubMed ID: 20308381
[TBL] [Abstract][Full Text] [Related]
14. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
[TBL] [Abstract][Full Text] [Related]
15. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
Mo H; Lu L; Pilot-Matias T; Pithawalla R; Mondal R; Masse S; Dekhtyar T; Ng T; Koev G; Stoll V; Stewart KD; Pratt J; Donner P; Rockway T; Maring C; Molla A
Antimicrob Agents Chemother; 2005 Oct; 49(10):4305-14. PubMed ID: 16189112
[TBL] [Abstract][Full Text] [Related]
16. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
Qi X; Bae A; Liu S; Yang H; Sun SC; Harris J; Delaney W; Miller M; Mo H
Antiviral Res; 2009 Feb; 81(2):166-73. PubMed ID: 19063924
[TBL] [Abstract][Full Text] [Related]
17. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
18. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
Binder J; Tetangco S; Weinshank M; Maegley K; Lingardo L; Diehl W; Love R; Patick AK; Smith GJ
Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
[TBL] [Abstract][Full Text] [Related]
19. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
[TBL] [Abstract][Full Text] [Related]
20. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
Lin K; Kwong AD; Lin C
Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
